Company Profile · Health · Artificial Intelligence
Us2.ai
The Singapore medtech teaching machines to read the human heart - one echocardiogram at a time.
The Singapore medtech teaching machines to read the human heart - one echocardiogram at a time.
An echocardiogram is one of medicine's most common windows into the heart. A sonographer glides a probe across a patient's chest, sound waves bounce back, and the beating heart appears on screen. But the picture is only half the job. Someone still has to measure the chambers, trace the valves, calculate the ejection fraction and write it all into a report - a process that can take a skilled reader many minutes per study, and that depends on expertise many clinics simply do not have on hand.
Us2.ai was built to close that gap. The company makes software that takes a raw echo study - the DICOM files straight off the ultrasound cart - and returns a complete, fully editable clinical report in seconds, with no manual clicks or tracing. It measures dozens of parameters automatically and flags disease patterns from heart failure and aortic stenosis to pulmonary hypertension and cardiac amyloidosis.
The pitch is not that AI replaces the cardiologist. It is that the cardiologist starts from a finished draft instead of a blank one. In an echo lab where reporting capacity limits how many patients can be seen, and where specialist time is the scarcest resource, that shift changes the math of the whole department.
Founded in Singapore in 2017 under the name eko.ai, the company rebranded to Us2.ai in 2021 after winning its first US FDA clearance. Today its platform - marketed as an "AI Echo Copilot" - is cleared by the FDA, CE marked in Europe and, the company says, active in more than 28 markets.
Figures per company disclosures; deployment and scan counts are self-reported.
Us2.ai's platform is vendor-neutral by design, running on images from GE, Philips and Siemens carts as well as handheld point-of-care ultrasound devices. It deploys in the cloud or on-premise and plugs into hospital PACS and cardiovascular information systems. The lineup has grown from a single automated report into a family of disease-specific models.
The first fully automated echo decision-support tool - analyzing 2D and Doppler images to produce a complete, editable report.
Next-generation platform measuring roughly 45 automated echo parameters and adding strain (GLS) imaging.
Zero-click, real-time reports and disease detection across heart failure, aortic stenosis, pulmonary hypertension and stress echo.
Deep-learning model that flags cardiac amyloidosis from a standard echo view - catching disease that "normal" reads can miss.
The bottleneck in cardiac ultrasound is not the scan - it is the reading and reporting that follow, plus the shortage of specialists to do it. Us2.ai's argument is a throughput argument: shave the reporting time and each lab can see more patients with the same staff.
Company-reported efficiency figures. Bar for "+2 exams" is illustrative, not to scale.
"AI will not replace a physician, but a physician using AI will replace a physician not using AI."
- Dr. Wojciech Mazur, cardiologistUs2.ai's origin is not a garage - it is a heart clinic. The company pairs commercial leadership with genuine cardiology credentials, a combination that shows up in its evidence-first approach to selling software into hospitals.
Dr. Carolyn Lam is a globally recognized heart-failure cardiologist affiliated with the National Heart Centre Singapore and Duke-NUS Medical School. Dr. Yoran Hummel is an echocardiography researcher who founded an imaging core lab in Groningen. Together with CEO James Hare, they built a company where the clinical voice sits at the founding table, not on an advisory panel.
The echo-AI field is crowded. Ultromics, DiA Imaging Analysis and Caption Health all work on cardiac ultrasound, while others such as UltraSight and ThinkSono focus on guiding image acquisition. What distinguishes Us2.ai is the breadth of a fully automated report combined with a heavy investment in published clinical evidence - work that has appeared in journals including Nature Communications and been tested in randomized trials presented at the American Heart Association's scientific sessions.
Two strategic choices reinforce that position. The first is vendor-neutrality: rather than lock in with a single ultrasound maker, Us2.ai works across carts and handheld devices, then extends reach through OEM and reseller deals with GE HealthCare, Fujifilm and, from 2026, Canon Medical Systems in the US. The second is regulatory depth - multiple FDA clearances and a CE Mark Class IIb certification, the kind of paperwork that functions as a moat in medical software.
B2B software licensing - subscription or per-study - sold into hospitals, echo labs and clinical-trial core labs, deployed cloud or on-premise and distributed through device-maker and regional reseller partners.
Hospitals, cardiology departments, academic medical centers and pharma research teams. Named users include Brigham and Women's Hospital, Duke University, Endeavor Health, Advara HeartCare and Juntendo University.
"Automating the fight against heart disease" - widening access to expert-level cardiac diagnostics regardless of geography or on-site specialist availability.
James Hare, Dr. Carolyn Lam and Dr. Yoran Hummel start the company in Singapore to automate echocardiography.
Investors including Sequoia Capital India and EDBI back the seed-stage company.
Us2.v1 wins FDA 510(k) clearance; the company rebrands from eko.ai to Us2.ai.
Round led by IHH Healthcare and HEAL Partners fuels global expansion.
Peer-reviewed clinical validation strengthens the company's evidence base.
Adds strain imaging and ~45 automated parameters; AI-ECHO randomized trial presented at AHA.
Cardiac amyloidosis detection cleared and CE marked; HCM model introduced; latest version earns CE Mark Class IIb.
Canon Medical USA reseller partnership and new health-system integrations expand deployment.
Backers included Sequoia Capital India and Singapore's EDBI.
Led by IHH Healthcare and HEAL Partners, with Pappas Capital, Sequoia Capital India, EDBI and Partech.
"Heal is delighted to support the company's mission to automate the fight against cardiovascular disease, the world's number one killer."
- Martin Robinson, HEAL PartnersIt makes FDA-cleared AI software that automatically analyzes echocardiograms (cardiac ultrasounds) and generates full, editable clinical reports in seconds - including detection of conditions like heart failure, aortic stenosis and cardiac amyloidosis.
Yes. Its platform is FDA 510(k) cleared and CE marked (Class IIb), available in 28+ markets, with SOC 2 Type II and ISO 27001 certifications.
It was founded in 2017 as eko.ai by James Hare (CEO), cardiologist Dr. Carolyn Lam and echocardiography researcher Dr. Yoran Hummel, and rebranded to Us2.ai in 2021.
Roughly US$20.7M in total, including a US$15M Series A in April 2022 led by IHH Healthcare and HEAL Partners, with Sequoia Capital India, EDBI, Partech and Pappas Capital.
Hospitals, cardiology and echo labs, academic medical centers and clinical-trial core labs. The company cites 500+ hospitals and over 1M scans analyzed.